Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.00105 USD | -12.50% |
|
-26.67% | -87.36% |
2023 | Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
2023 | Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval | CI |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Royalty/Licensing, Net
90.2
%
| 0 | 83.9 % | 0 | 90.2 % | +11.35% |
Direct Sales - Plastic Surgeons, Gross
9.8
%
| 0 | 16.1 % | 0 | 9.8 % | -36.86% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +3.61% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 59 | 01/12/01 |
Steven Barnes
IRC | Investor Relations Contact | - | 01/14/01 |
Corporate Officer/Principal | 68 | 01/22/01 | |
David Clark
SAM | Sales & Marketing | - | 03/19/03 |
Ira Weisberg
PRN | Corporate Officer/Principal | 75 | 30/22/30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 59 | 01/12/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 600 | 0 | 0 | 77.47 % |
Stock B | 1 | 349,394,357 | 270,662,701 ( 77.47 %) | 0 | |
Stock C | 0 | 25,000 | 0 | 0 |
Company contact information
Endonovo Therapeutics, Inc.
6320 Canoga Avenue 15th Floor
91367, Woodland Hills
+800 489 4774
http://www.endonovo.com![address Endonovo Therapeutics, Inc.(ENDV)](https://cdn.zonebourse.com/static/address/111313954.png)
Sector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
-87.36% | 4L | |
+15.20% | 12TCr | |
+19.67% | 11TCr | |
+18.95% | 2.6TCr | |
-23.86% | 1.94TCr | |
-19.03% | 1.59TCr | |
-20.90% | 1.51TCr | |
-46.14% | 1.51TCr | |
+63.85% | 1.49TCr | |
+4.49% | 1.39TCr |
- Stock Market
- Equities
- ENDV Stock
- Company Endonovo Therapeutics, Inc.